_ 10 October 2024 | 7:30AM CST | --- | --- | --- | --- | --- | --- | --- | |-------|-----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------- ...

Equity Research Report Ganyuan Foods (002991 CH) Revenue Growth Slowed in 2024, 3Y Dividend Plan Announced Huatai ResearchInterim Results Review 14 August 2024 | China (Mainland)Food Qoq slowdown in 2Q24 due to off-season and personnel adjustments Ganyuan Foods' (Ganyuan) revenue/attributable net profit (NP)/recurring NP were RMB1,040/170/140mn for 1H24 (+26.1/+39.3/+40.0% yoy) and RMB460/80/60mn for 2Q24 (+4.9/+16.9/+13.6% yoy). In 2Q24, revenue fell during the off-season for snack sales. This, coupled wit ...

Investment Rating - Maintain Buy rating on Wanhua Chemical Group (600309 SS) with a revised 12-month target price of Rmb106 0 per share, up from Rmb103 0 [2][5] Core Thesis - The polyurethane cycle is bottoming out, with volume recovery across major players and sequentially improved pricing, although spread recovery was delayed due to high raw material prices [3] - Wanhua Chemical is well-positioned for cyclical recovery, with a leading position in one of the most consolidated commodity chemical supply chains and long-term structural growth opportunities [8] - The company is expected to grow earnings at a +c 20% CAGR over 2023-26E, driven by new capacity projects for high-margin specialty chemicals and normalization of petrochemical earnings [6][8] Financial Estimates - 2024E-26E EPS estimates reduced by 5-9% to reflect weaker-than-expected margins in performance chemicals and new materials segment, higher opex, impairment losses, and finance expenses [2] - 2024E revenue estimate revised to Rmb198 310mn (from Rmb199 624mn), 2025E to Rmb228 460mn (from Rmb231 413mn), and 2026E to Rmb261 360mn (from Rmb262 856mn) [5] - 2024E net profit estimate revised to Rmb16 670mn (from Rmb18 227mn), 2025E to Rmb22 071mn (from Rmb24 199mn), and 2026E to Rmb26 748mn (from Rmb28 149mn) [5] Valuation and Catalysts - Target EV/EBITDA multiple slightly lowered to 10 5x (from 11 0x) to reflect reduced growth forecasts, but valuation base year rolled forward to average 2024E-25E [2] - Potential catalysts include US rate cuts and improving construction activities in Europe in early-mid 2025, which should support recovery in polyurethane demand and drive pricing/margin upside [2] - Strong pipeline of new capacity projects for high-margin specialty chemicals (e g , polyolefin elastomers and flavor and fragrance) scheduled to come on stream in 2H24 [3] Industry Position - Wanhua Chemical is the largest global producer of MDI (30% share of 2023 global capacity) and TDI (25% share of 2022 capacity) [6] - The company accounts for ~80% of global new polyurethane supply over 2023-25E, with continued volume share gains expected [6]

Investment Rating - The investment rating for Angel Yeast is maintained as BUY with a target price of RMB 38.39, indicating a potential upside of 24% from the closing price of RMB 30.87 as of August 12, 2024 [8][9]. Core Insights - Angel Yeast reported 2Q24 earnings that exceeded expectations, with revenue and net profit showing significant year-on-year growth of 11.3% and 17.3% respectively. The company is expected to resume growth momentum due to increased demand in its main business and improved overseas performance [3][4]. - The gross profit margin (GPM) for 2Q24 rose by 0.3 percentage points year-on-year to 23.9%, attributed to faster revenue growth from high-margin products and declining molasses prices, which are expected to reduce cost pressures [5][6]. - The company has revised its earnings forecasts upward, projecting EPS of RMB 1.60, RMB 1.80, and RMB 2.07 for 2024, 2025, and 2026 respectively, reflecting a positive outlook on domestic demand recovery and overseas market expansion [5][6]. Revenue and Profit Performance - For 1H24, Angel Yeast's revenue reached RMB 7,180 million, with attributable net profit of RMB 690 million, marking a year-on-year increase of 6.9% and 3.2% respectively. The overseas revenue grew by 17.9% year-on-year, while domestic revenue saw a modest increase of 0.9% [3][4]. - The performance of various product segments showed mixed results, with yeast and deep processing products increasing by 8.8% year-on-year, while sugar and packaging segments experienced declines of 26.5% and 12.8% respectively [4]. Financial Projections - The financial outlook for Angel Yeast includes projected revenues of RMB 14,969 million, RMB 16,629 million, and RMB 18,364 million for 2024, 2025, and 2026 respectively, indicating a steady growth trajectory [7][13]. - The company’s net profit is expected to reach RMB 1,390 million, RMB 1,565 million, and RMB 1,799 million for the same years, reflecting a positive growth trend [7][13].

Equity Research Report By-health (300146 CH) Revenue Down on High Base, Profit Dented on Increased Expenses Huatai ResearchInterim Results Review 13 August 2024 | China (Mainland)Food Revenue slid on high base, profit constrained on increased expenses By-health's revenue/attributable net profit (NP)/recurring attributable NP were RMB4,610/890/830mn (-17.6/-42.3/-42.8% yoy) for 1H24 and RMB1,970/160/ 120mn (-20.9/-68.1/-73.5% yoy) for 2Q24. We attribute the temporary strain on earnings primarily to: 1) a hig ...

Investment Rating - The investment rating for Tasly Pharmaceutical is maintained at OVERWEIGHT, with a target price of RMB17.30, indicating a potential upside of 25% from the closing price of RMB13.85 as of August 9, 2024 [3][10][30]. Core Insights - The controlling shareholder of Tasly, Tasly Group, plans to transfer 28% of its share capital (approximately 418 million shares) to CR Sanjiu for a total consideration of around RMB6,212 million. This acquisition is expected to enhance CR Sanjiu's industrial chain and leverage Tasly's expertise in traditional Chinese medicine and innovative pharmaceuticals [3][4]. - Tasly is projected to achieve attributable net profits of RMB1.18 billion, RMB1.31 billion, and RMB1.46 billion for the years 2024, 2025, and 2026, respectively, reflecting year-on-year growth rates of 10%, 11%, and 11% [3][4]. - The report anticipates stable business fundamentals for Tasly in 2024, with steady growth in its traditional Chinese medicine segment and a rally in sales volume for chemical drugs driven by the VBP program [5][6]. Summary by Sections Business Overview - Tasly is recognized as a leader in traditional Chinese medicine prescription drugs and has a strong R&D pipeline with 98 products in development. The company has developed blockbuster products such as Danshen and Yangxue Qingnao [4][5]. Financial Projections - Revenue is expected to grow from RMB8,593 million in 2022 to RMB10,506 million by 2026, with net profit projected to increase from a loss of RMB256.51 million in 2022 to RMB1,460 million in 2026 [8][15]. - The earnings per share (EPS) is forecasted to rise from a loss of RMB0.17 in 2022 to RMB0.98 in 2026 [8][15]. R&D and Innovation - Tasly has consistently invested in R&D, with annual expenses ranging from RMB600 million to RMB900 million since 2018, representing an R&D expense ratio of 5-10%. The company has independently developed over 20 novel TCM products, with several projects expected to submit NDAs starting in 2024-2025 [6][4]. Market Position - The acquisition by CR Sanjiu is expected to reshape Tasly's competitive landscape, integrating management systems and potentially adjusting business practices from 2025 onwards [4][5].

Equity Research Report Wens Foodstuffs (300498 CH) Rise in Meat Pig Selling Price Beat Average; Per-Head Profit Leading Huatai ResearchAnnouncement Comment 13 August 2024 | China (Mainland)Agribusiness Meat pig per-head profit neared RMB600 in July Wens Foodstuffs (Wens) saw sustained rises in pig and broiler output in July, with the selling price of meat pigs at RMB18.95/kg, above the industry average. We estimate its meat pig per-head profit at nearly RMB600. Given a potential contraction in hog supply in ...

Equity Research Report Jafron Biomedical (300529 CH) Earnings Grew Strongly in 2024 Huatai ResearchInterim Results Review 13 August 2024 | China (Mainland)Medical Devices Earnings growth continued to pace up in 2Q24; maintain BUY Jafron Biomedical (Jafron) registered 1H24 revenue/attributable net profit (NP) of RMB1,496/553mn (up 47.8/99.1% yoy) and 2Q24 revenue/attributable NP of RMB751/268mn (up 70.9/230.6% yoy), which further picked up from the growth rates in 1Q24 (revenue/attributable NP: up 30/44.9% y ...

Equity Research Report Canmax Technologies (300390 CH) Lithium Ore Price Falls Dented Earnings, Awaiting Turnaround Huatai ResearchInterim Results Review 13 August 2024 | China (Mainland)Other New Materials & Processing 1H24 attributable NP down 39.26% yoy, maintain OVERWEIGHT Canmax has posted its interim results, with 1H24 revenue/attributable net profit (NP)/recurring NP down 44.09/39.26/55.92% yoy to RMB3,713/835/523mn. For 2Q24, revenue/attributable NP arrived at RMB1,959/333mn (-36.89/-32.49% yoy, +11 ...

9 August 2024 | 10:36PM HKT _ Focus Media Information Tech (002027.SZ) 2Q24 Review: Accelerating ad revenue with 5% dividend yield; Buy Buy 0007.SZ 12mPrie Target: Rmb7.50 Prie: Rmb5.78 Upside: 9.8% We maintain our Buy rating on Focus Media while raise our 12-m TP to Rmb7.5 (30% upside) post its strong 2Q24 results (see our note) and mgmt call.The stock has dropped 3% post results despite the headline revenue beat (+10% yoy vs. ÍGSe of +4%, Visible Alpha Consensus of +4%), NI beat (+13% yoy, 9% ahead of GSe ...